Included in the formulation
АТХ:H.01.C.B Hormones that slow growth
H.01.C.B.03 Lanreotide
Pharmacodynamics:Synthetic peptide, analogue of somatostatin. It inhibits the endocrine, exocrine and paracrine mechanisms of somatotropin, to a greater extent tropen to peripheral somatostatin receptors, therefore it acts selectively for the secretion of growth hormone, pancreas glands (insulin, glucagon, digestive enzymes) and intestines (gastrin).
Pharmacokinetics:In the first phase, rapid release of the peptide occurs, in the second - a slow release. The maximum concentration of the drug in the first phase is achieved after 0.5-2 hours; in the second phase - after 1-3 days.
The half-life is 2-7 days.
The concentrations of insulinotropic growth factor and growth hormone decrease within 14 days after a single administration of the drug. With continuous administration of the drug, no phenomena of cumulation were noted.
Indications:It is used for the relief of symptoms of carcinoid tumors, as well as for acromegaly, when surgical treatment, radiotherapy and the use of dopaminomimetics were not effective enough. Used to treat fistula of the gastrointestinal tract,which appeared as a result of surgical intervention.
IV.E20-E35.E22.0 Acromegaly and pituitary gigantism
IV.E20-E35.E34.0 Carcinoid Syndrome
Contraindications:Individual intolerance.
Pregnancy and lactation:Recommendations for FDA - Category D. During pregnancy and lactation, the use of the drug is contraindicated.
Dosing and Administration:Intramuscularly, 30 mg once every 14 days. With insufficient effectiveness, the interval between injections is reduced to 10 days. The duration of treatment is determined individually.
In the treatment of the fistula of the digestive tract, the drug is applied once every 10 days until complete healing. The maximum number of injections is 4.
The highest daily dose: 30 mg.
The highest single dose: 30 mg.
Side effects:Local reactions: pain, burning, itching at the injection site.
Gastrointestinal tract: diarrhea, steatorrhea, nausea, flatulence. With prolonged use, it is possible to develop asymptomatic cholelithiasis.
Endocrine system: change in glucose tolerance.
Allergic reactions.
Overdose:Violations of electrolyte blood composition. Treatment is symptomatic.
Interaction:Simultaneous use with insulin enhances its hypoglycemic effect.
Reduces the concentration of cyclosporine in the blood plasma.
Special instructions:Monitoring the content of glucagon, insulin in the blood. Adjustment of insulin doses for diabetes mellitus.
Obligatory ultrasound examination of the gallbladder before treatment and every 6 months.